Investors in Eli Lilly and Company (NYSE:LLY) have benefited from its solid execution in its well-diversified portfolio and pipeline as the market rewarded LLY for its ability to drive potentially significant upside.
Keen investors should know that Lilly is a leading big pharma with a leading portfolio in tackling diabetes, obesity, Alzheimer’s disease, and autoimmune disorders.
The market has rewarded the company’s potential breakthroughs in its new and growth products, which bolstered its performance in Q1. In addition, Lilly’s competitive advantage in its core diabetes products helps to undergird its wide economic moat, creating significant barriers to entry for generics in attempting to replicate its scale.
The company’s ability to drive scale efficiencies through large-scale production processes cannot be further overstated. Management updated in a recent June conference that “manufacturing and supply decisions are strategic and made well in advance of product launches.”
As such, Lilly’s $1.7B investment in its new North Carolina facility was prepared before the company had “full data on tirzepatide and understanding market demand.”
Mounjaro (Tirzepatide) and Trulicity are important growth drivers for Lilly. Mounjaro is “currently in Phase 3 clinical trials for obesity,” with the recent positive data highlighting the potential to combat obesity effectively.
In addition, Lilly stressed that the “actual data exceeded expectations.” As such, it undergirded stronger adoption and underlying demand for Tirzepatide, providing the impetus for healthcare investors in a difficult year so far.
Accordingly, Health Care Select Sector SPDR ETF (XLV) has significantly underperformed the S&P 500 (SPY) (SPX) in 2023, with a total return of -4.3% compared to SPY’s 15.6% uptick. As such, I assessed the broad healthcare sector remains undervalued, as several leading stocks were battered in the first half of 2023.
However, LLY bucked the sector’s trend in 2023, delivering a YTD total return of 24.3%. Notably, LLY has significantly outperformed XLV over the past five to ten years in total return terms, indicating the market’s confidence in Lilly’s execution and portfolio potential.
Wall Street analysts are also optimistic about the company’s ability to drive topline growth and operating leverage over the next three to four years. Lilly is projected to achieve a 5Y revenue CAGR of 15.5% from 2022-27. In addition, it’s expected to deliver an adjusted operating profit growth of 24.3% over the same period. I assessed that these are spectacular growth metrics for a big pharma player, with revenue expected to reach $31.4B in 2023.
Seeking Alpha Quant also rated LLY’s growth profile with a “B+” grade, suggesting that LLY is priced for growth. Undergirded by solid profitability (rated “A+” by Quant), Lilly is well-positioned to capitalize on its portfolio and pipeline as it continues to make R&D a core focus of its spending profile.
However, the critical question facing investors is whether the current levels are still reasonable for them to add further?
LLY forward EBITDA multiples trend (Koyfin)
As seen above, LLY last traded at a forward EBITDA multiple of more than 39x, well above its 10Y average of 17.4x. Considering its potentially significant operating profit growth, I gleaned that the market has likely priced in a relatively successful outcome of its current portfolio and pipeline over the next four years.
Based on its FY27 projections, LLY is assessed to trade at an FY27 EBITDA multiple of 17x. Therefore, the market seems to have reflected its growth profile over the next four years, leaving little room for execution or market definition challenges.
Despite its overvaluation, LLY’s price action remains well-anchored in a long-term uptrend, with no strong sell signals. While I gleaned that a pullback is increasingly likely to help digest some of its recent optimism, I have yet to see a reason for investors to cut significant exposure in LLY.
As such, investors should consider holding through potential near-term volatility and adding on sharp pullbacks to improve the risk/reward profile. For now, stay on the sidelines.
Rating: Hold.
Important note: Investors are reminded to do their own due diligence and not rely on the information provided as financial advice. The rating is also not intended to time a specific entry/exit at the point of writing unless otherwise specified.
We Want To Hear From You
Have additional commentary to improve our thesis? Spotted a critical gap in our thesis? Saw something important that we didn’t? Agree or disagree? Comment below and let us know why, and help everyone in the community to learn better!
Read the full article here
